The House Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies has advanced a fiscal year 2027 spending bill that explicitly prohibits federal workers’ compensation programs from covering medical marijuana expenses. The 11-7 vote underscores a persistent legislative barrier at the federal level, persisting despite ongoing administrative discussions regarding the rescheduling of cannabis. By including this provision, the committee is setting a precedent that federal reimbursement policies will remain restrictive regardless of potential shifts in the Controlled Substances Act or DEA status.
This legislative move serves as a buffer against the integration of medical cannabis into federal employee benefits packages. While the bill must still pass through full committee and floor votes, its advancement signifies that lawmakers are taking proactive steps to maintain the status quo concerning federal funding and cannabis-related medical costs. For industry stakeholders, this decision highlights that regulatory progress at the federal level—such as rescheduling—does not automatically equate to the normalization of cannabis within federal insurance or compensation frameworks.
This creates a distinct separation between potential state-legal cannabis markets and the rigid requirements of federal benefit programs. Businesses operating in the medical cannabis sector should note that the path to insurance coverage for patients remains fraught with legislative obstacles, even as federal classification of the plant potentially changes in the coming years.